Avantor’s (AVTR) Outperform Rating Reiterated at Raymond James

Raymond James reissued their outperform rating on shares of Avantor (NYSE:AVTR) in a report issued on Monday morning,Benzinga reports. The brokerage currently has a $24.00 price target on the stock, down from their previous price target of $26.00.

Several other brokerages have also commented on AVTR. Royal Bank of Canada dropped their price target on shares of Avantor from $33.00 to $31.00 and set an “outperform” rating for the company in a research report on Monday. Wells Fargo & Company dropped their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday. UBS Group reaffirmed a “neutral” rating and set a $25.00 price target (down previously from $29.00) on shares of Avantor in a research report on Friday, January 17th. Stifel Nicolaus dropped their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research report on Monday. Finally, Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.15.

Avantor Stock Performance

Shares of AVTR opened at $18.06 on Monday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The company has a market capitalization of $12.29 billion, a price-to-earnings ratio of 39.26, a PEG ratio of 3.87 and a beta of 1.28. The company’s 50 day simple moving average is $21.63 and its 200 day simple moving average is $23.39. Avantor has a 1 year low of $18.00 and a 1 year high of $28.00.

Avantor (NYSE:AVTR) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter in the prior year, the business earned $0.22 EPS. On average, sell-side analysts predict that Avantor will post 0.98 EPS for the current year.

Institutional Investors Weigh In On Avantor

Several large investors have recently made changes to their positions in AVTR. MassMutual Private Wealth & Trust FSB increased its position in shares of Avantor by 99.5% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after acquiring an additional 625 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in Avantor by 106.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock valued at $34,000 after purchasing an additional 830 shares in the last quarter. UMB Bank n.a. acquired a new stake in Avantor during the 3rd quarter valued at $49,000. Global Retirement Partners LLC grew its holdings in Avantor by 76.7% during the 4th quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock valued at $52,000 after purchasing an additional 1,067 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its holdings in Avantor by 69.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock valued at $53,000 after purchasing an additional 835 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.